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Rodrigues Dias, Ana Carolina, and Eduardo Colombari. Cen-
tral nitric oxide modulates hindquarter vasodilation elicited by AMPA
receptor stimulation in the NTS of conscious rats. Am J Physiol Regul
Integr Comp Physiol 290: R1330–R1336, 2006. First published De-
cember 29, 2005; doi:10.1152/ajpregu.00150.2005.—Microinjection
of S--amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) in
the nucleus of the solitary tract (NTS) of conscious rats causes
hypertension, bradycardia, and vasoconstriction in the renal, mesen-
teric, and hindquarter vascular beds. In the hindquarter, the initial
vasoconstriction is followed by vasodilation with AMPA doses 5
pmol/100 nl. To test the hypothesis that this vasodilation is caused by
activation of a nitroxidergic pathway in the NTS, we examined the
effect of pretreatment with the nitric oxide synthase inhibitor NG-
nitro-L-arginine methyl ester (L-NAME, 10 nmol/100 nl, microin-
jected into the NTS) on changes in mean arterial pressure, heart rate,
and regional vascular conductance (VC) induced by microinjection of
AMPA (10 pmol/100 nl in the NTS) in conscious rats. AMPA
increased hindquarter VC by 18  4%, but after pretreatment with
L-NAME, AMPA reduced hindquarter VC by 16  7% and 17  9%
(5 and 15 min after pretreatment, P  0.05 compared with before
pretreatment). Pretreatment with L-NAME reduced AMPA-induced
bradycardia from 122  40 to 92  32 beats/min but did not alter the
hypertension induced by AMPA (35  5 mmHg before pretreatment,
43  6 mmHg after pretreatment). Control injections with D-NAME
did not affect resting values or the response to AMPA. The present
study shows that stimulation of AMPA receptors in the NTS activates
both vasodilatatory and vasoconstrictor mechanisms and that the vasodi-
latatory mechanism depends on production of nitric oxide in the NTS.
nitric oxide synthase; regional vascular conductance; cardiovascular
regulation
THE PRESSOR RESPONSE and bradycardia elicited by microinjec-
tion of L-glutamate into the nucleus of the solitary tract (NTS)
of conscious rats are associated with vasoconstriction in the
hindquarter, renal, and mesenteric vascular beds. A subsequent
vasodilation occurs in the hindquarter bed (4). A similar
pattern of an initial general vasoconstriction followed by hind-
quarter vasodilation can be seen after stimulation of S--
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors in the NTS (9). The vasodilation produced by microin-
jection of glutamate in the NTS can be reduced by systemic
administration of prazosin and NG-nitro-L-arginine methyl ester
(L-NAME) (4). The origin and pathway involved in this neuro-
genic vasodilation is still unclear (4), but it was suggested that this
vasodilation is caused by peripheral release of preformed nitrosyl
factors during sympathetic stimulation (6, 7).
Interactions between nitric oxide (NO) and glutamatergic
transmission within the NTS on cardiovascular regulation have
been shown by anatomic and physiological studies (24, 25, 27,
29, 34, 36, 41). All of the substrates necessary for NO produc-
tion are present in the NTS. Activation of glutamatergic recep-
tors in the NTS stimulates the production and release of NO
and other nitrosyl substances with neurotransmitter/neuro-
modulator properties (11, 34). Microinjection of inhibitors of
the enzyme for synthesis of NO, nitric oxide synthase (NOS),
reduces the basal glutamate level (24). On the other hand, NO
donors, L-arginine, and L-glutamate cause hypotension and
bradycardia when microinjected into the NTS of anesthetized
rats (32, 33, 42).
L-glutamate and NOS are colocalized in nerve terminals and
neurons in the NTS (13, 17–19, 23, 25), and NOS immunore-
activity is found in other neurons in the medulla oblongata that
project to the NTS (2, 13, 37). Centrally released NO has been
considered as a retrograde messenger that modulates long-term
potentiation or depression (40). Long-term potentiation in-
volves the activation of N-methyl-D-aspartate (NMDA) and
AMPA receptors (12). Brain NO synthesis seems to be regu-
lated by the influx of calcium through receptor-dependent
channels, particularly glutamate receptors located in the
postsynaptic membrane (3, 12, 15). NO diffuses from the nerve
terminals and may act on adjacent cells (2, 13).
The neuromodulatory effect of NO in the central nervous
system (CNS) has been widely investigated. We previously
showed that iontophoresis of L-NAME on NTS neurons receiv-
ing vagal afferent inputs did not alter spontaneous discharge
but significantly decreased the number of action potentials
evoked by iontophoretic application of AMPA (8). In addition,
iontophoresis of the NO donor PAPANONOate enhanced
spontaneous discharge and the number of action potentials
elicited by AMPA, suggesting that NO could be facilitating
AMPA-mediated neuronal transmission within the NTS (8).
Furthermore, the changes in renal sympathetic discharge dur-
ing activation of baroreceptors and cardiopulmonary receptors
involve activation of AMPA and NMDA receptors in the NTS
(10, 38), and these responses are attenuated by microinjection
of L-NAME in the NTS (10). Cardiovascular responses elicited
by application of NO in the NTS are closely similar to those
obtained after activation of vagal afferent inputs, and L-gluta-
mate is the main neurotransmitter of vagal afferent fibers (23).
The presence of NOS, including the protein nNOS (neuronal
NOS) and its mRNA, in vagal afferent terminals (17, 22, 28) in
the NTS and nodose ganglion cells suggests that NO can act on
Address for reprint requests and other correspondence: E. Colombari, Dept.
of Physiology, Universidade Federal de Sa˜o Paulo-EPM, 862 Botucatu St., Sa˜o
Paulo SP 04023-60, Brazil (e-mail: colombari@fcr.epm.br).
The costs of publication of this article were defrayed in part by the payment
of page charges. The article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Am J Physiol Regul Integr Comp Physiol 290: R1330–R1336, 2006.
First published December 29, 2005; doi:10.1152/ajpregu.00150.2005.
0363-6119/06 $8.00 Copyright © 2006 the American Physiological Society http://www.ajpregu.orgR1330
glutamatergic transmission. Therefore, we sought to investi-
gate whether NO plays a neuromodulatory role in cardiovas-
cular regulation through regional hemodynamic changes elic-
ited by AMPA receptor stimulation within the NTS of non-
anesthetized rats.
MATERIALS AND METHODS
Animals. Experiments were performed in conscious, freely moving,
male Wistar rats weighing between 280 and 350 g. Animals were
maintained on 12:12-h light-dark cycle in temperature-controlled
rooms. Food and water were available ad libitum except during the
experiments. All experimental protocols were approved by the Insti-
tutional Ethics Committee.
Surgical procedures. All surgical procedures, including implanta-
tion of guide cannulas, blood flow probes, and femoral arterial
catheters, were performed as described previously by Dias et al. (9).
Briefly, 5 days before the experiments, rats were anesthetized with
ketamine (50 mg/kg ip; Holliday-Scott, Buenos Aires, Argentina) and
placed in a stereotaxic frame (model 1940; David Kopf Instruments)
with the incisor bar fixed at 3.5 mm. Guide cannulas aimed at the
NTS were implanted bilaterally at the following stereotaxic coordi-
nates: 14.5 mm caudal to bregma, 0.5 mm lateral to the midline, and
5.5 mm below the skull surface at the level of bregma. The guide
cannula was fixed with methacrylate to the skull and to watch screws
inserted in the skull. An occluder closed the cannula until the start of
the experiments. The animals were allowed to recover fully from
anesthesia and were kept in their home cages for 3–5 days. Forty-eight
hours before the experiments were performed, rats were anesthetized
with a mixture of halothane (2%) in oxygen (100%), and a cannula
(PE-10 connected to PE-50; Clay Adams, Parsippany, NJ) was im-
planted in the femoral artery for measurement of pulsatile arterial
blood pressure (PAP), mean arterial pressure (MAP), and heart rate
(HR). After catheterization, a midline laparotomy was performed, and
miniature pulsed Doppler flow probes (Iowa Doppler Products, Iowa
City, IA) were placed around the lower abdominal aorta (1.3 mm of
lumen), superior mesenteric artery (1.0 mm of lumen), and left renal
artery (0.8 mm of lumen) for measurement of hindquarter, mesenteric,
and renal blood flow, respectively. The probes were sutured in place,
the leads and the catheter were tunneled subcutaneously and exteri-
orized between the scapulae, and the wounds were closed. To protect
the probe wires and the polyethylene tubing while allowing the animal
unrestricted movement, we passed the free ends of the catheters and
the Doppler leads through a stainless steel skin button connected to a
spring and swivel assembly. The assembly was mounted to a ring
stand clamp and suspended above the cage. The skin button was
attached to the skin incision in the scapular region with stainless steel
sutures. To avoid contamination and minimize postoperative pain, we
performed all procedures with sterile tools and solutions. Animals that
seemed to show distress or pain after surgeries were euthanized.
Drug administration. The arterial catheter was connected to a
Statham P23Db transducer and to a ETH-200 Bridge amplifier (CB
Sciences). Flow probe leads were connected to a Doppler flowmeter
(Department of Bioengineering, University of Iowa, Iowa City, IA).
PAP (mmHg), MAP (mmHg), HR (beats/min), and hindquarter, renal,
and mesenteric regional blood flows (kHz) were recorded in conscious
animals after recovery from instrumentation (48 h). Signals were
obtained using a digital data acquisition system (PowerLab with Chart
version 3.4s; AD Instruments) and monitored on a Macintosh com-
puter (G3; Apple). Drug microinjections into the NTS were made with
a needle (33-gauge) that protruded 1.5 mm beyond the tip of the guide
cannula. The needle was connected with PE-10 tubing to a 1-l
syringe (Hamilton, Reno, NV). Microinjections of AMPA hydrobro-
mide (AMPA HBr, a glutamatergic ionotropic agonist; RBI) and
NG-nitro-L-arginine methyl ester (L-NAME, an NOS inhibitor; Sigma)
or NG-nitro-D-arginine methyl ester (D-NAME, the inactive enantio-
mer of L-NAME; Sigma) were made unilaterally after baseline hemo-
dynamic values were established.
Protocols. Hemodynamic effects produced by AMPA injections in
the NTS (10 pmol/100 nl) were determined before (control) and 5, 15,
and between 30 and 45 min after microinjection of L-NAME or
D-NAME (10 nmol/100 nl) into the NTS. L-NAME or D-NAME was
injected 20 min after the AMPA control microinjection. The volume
of all injections was 100 nl. The dose of AMPA used in this study (10
pmol) consistently induced hindquarter vasodilation in a previous
study (9). The dose of L-NAME used in this study is considerably less
than that used to block NOS peripherally. We have shown before that
microinjection of 10 nmol/100 nl into the NTS does not change
resting blood pressure, heart rate, regional blood flow, renal sympa-
thetic nerve activity (10), or resting neuronal discharge of vagus
nerve-evoked NTS neurons (8).
Histology. After the experiments, methylene blue (100 nl of a 2%
solution) was microinjected in the same NTS site for histological
analysis. Animals were anesthetized with pentobarbital sodium (1g/kg
iv) and perfused transcardially with saline (0.9%) followed by 10%
formalin solution. The brain was removed and stored in buffered
formalin for at least 2 days. Coronal sections (40 m) were cut on a
microtome and stained using the Nissl method (16). Only rats whose
microinjection sites were located in the intermediate NTS were used
for data analysis (Fig. 1).
Data analysis. Relative mesenteric, renal, and hindquarter vascular
conductances (MVC, RVC, and HVC, %) were calculated as the ratio
of Doppler shift and MAP, and they were expressed as percentages of
the baseline as described previously by Dias et al. (9). Responses were
divided into phases to facilitate data analysis: maximum hypotension
defined phase I, maximum hypertension defined phase II, and maxi-
mal hindquarter vasodilation defined phase III. The timing (period) to
define each phase on AMPA cardiovascular responses was the same
before and after L-NAME or D-NAME treatment. When a phase was
not present or did not occur after the treatment, its corresponding
timing in the control response was taken for analysis. All data are
expressed as means  SE and were analyzed using SigmaStat statis-
tical software (version 2.03; SPSS). One-way ANOVA with repeated
measures was used to compare differences between time points
(control, 5 min, 15 min, and 30–45 min), and the Newman-Keuls post
hoc test was used to identify values that were significantly different
from control values. Significance was set at P  0.05.
Fig. 1. Photomicrography of a coronal section of the brainstem showing a
typical unilateral microinjection site in the nucleus of the solitary tract (NTS).
Arrow indicates the center of microinjections. AP, area postrema; cc, central
canal; X, dorsal motor nucleus of vagus; XII, hypoglossal nucleus; TS, solitary
tract. Scale: 3 cm correspond to 1 mm of neural tissue.
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RESULTS
Effects of central NOS inhibition on changes in MAP and
HR induced by microinjection of AMPA in the NTS. A group of
six rats (baseline MAP: 108  3 mmHg; baseline HR: 340 
22 beats/min) received unilateral microinjection with 10 pmol/
100 nl AMPA in the intermediate NTS before microinjection
of L-NAME and then 5, 15, and 30–45 min after L-NAME (10
nmol/100 nl). Figure 2 (left) shows a typical example of the
hemodynamic effects caused by AMPA in a conscious rat in
the absence of L-NAME (AMPA control). The response con-
sists of a period of hypotension (phase I, MAP control:
16  11 mmHg) followed by a longer lasting period of
hypertension (phase II, MAP control: 35  5 mmHg, P 
0.05). Phase III is defined by the peak of hindquarter vasodi-
lation. By this time, MAP was still elevated (MAP control:
19  4 mmHg, P  0.05) but was falling back to baseline
(Figs. 2 and 3A). The initial hypotension caused by AMPA
(phase I) is the result of intense bradycardia (HR control:
122  40 beats/min, P  0.05; Fig. 3B) that may decrease
cardiac output. This response can be abolished with intrave-
nous methylatropine treatment, as we previously reported (9).
The large variation in AMPA-mediated hypotension can be
related to the variability in HR fall, considering that experi-
ments were performed on nonanesthetized, freely moving rats.
Unilateral microinjection of L-NAME (10 nmol) into the
NTS of conscious rats did not change baseline MAP (MAP
before L-NAME: 112  6 mmHg vs. MAP after L-NAME:
114  5 mmHg) or baseline HR (HR before L-NAME: 369 
30 beats/min vs. HR after L-NAME: 316  28 beats/min).
AMPA-induced changes in MAP were not affected by L-
NAME (phase II, MAP before L-NAME: 35  5 mmHg;
phase II, MAP 15 min after L-NAME: 43  6 mmHg; Fig.
3A). Microinjection of L-NAME in the NTS did not signifi-
cantly alter the bradycardia induced by AMPA (phase I, HR
before L-NAME: 122  40 beats/min; phase I, HR 5 min
after L-NAME: 163  55 beats/min; phase I, HR 15 min
after L-NAME: 92  32 beats/min; Fig. 3B).
Effects of central NOS inhibition on regional vascular con-
ductance responses to NTS microinjection of AMPA. The ratio
of Doppler shift (blood flow) and MAP was used to calculate
Fig. 2. Typical tracing showing changes in pulsatile arterial pressure (PAP, mmHg), mean arterial pressure (MAP, mmHg), heart rate [HR, beats/min (bpm)],
renal blood flow (RBF, kHz), mesenteric blood flow (MBF, kHz), and hindquarter blood flow (HBF, kHz) elicited by unilateral microinjection of
S--amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA; 10 pmol/100 nl) before (control), during, and 5, 15, and 45 min after unilateral microinjection
of the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 10 nmol/100 nl) into the NTS of conscious rats. I, II, and III indicate
phase I (peak fall of arterial pressure), phase II (peak rise of arterial pressure), and phase III (peak elevation of HBF), respectively.
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relative HVC, RVC, and MVC. In the absence of L-NAME,
microinjection of AMPA (10 pmol/100 nl) in the NTS reduced
HVC (vasoconstriction) in phase I (phase I, HVC control:
21  10%). Phase II is the period of maximal blood
pressure, but with respect to blood flow it is a transitional phase
in which vascular conductance is still reduced (phase II,
HVC control: 11  8%) but returning to baseline. Vaso-
dilation is observed in the hindquarter bed in phase III (phase
III, HVC control: 18  4%, P  0.05) (Fig. 3C).
After microinjection of L-NAME into the NTS, the maxi-
mum vasoconstriction induced by AMPA first obtained in
phase I shifted to phase II (phase II, HVC control: 11 
8%; phase II, HVC 5 min after L-NAME: 61  7%; phase
II, HVC 15 min after L-NAME: 30  7%; and phase II,
HVC 45 min after L-NAME: 39  9%, P  0.05, n  6).
Vasodilation observed in phase III was abolished in AMPA
microinjections performed 5 and 15 min after L-NAME (phase
III, HVC control: 18  4%; phase III, HVC 5 min after
L-NAME: 16  7%; and phase III, HVC 15 min after
L-NAME: 17  9%, P  0.05, n  6). The response to
AMPA began to recover by 45 min after L-NAME (phase III,
HVC 45 min after L-NAME: 3  6%). Changes in HVC
caused by AMPA at 5, 15, and 45 min after L-NAME are
shown in Fig. 3C.
AMPA (10 pmol/100 nl) microinjected into the NTS caused
significant vasoconstriction in the renal and mesenteric beds
during phase II (phase II, RVC control:35 8%; phase II,
MVC control: 36  6%, P  0.05, n  5). Vasoconstric-
tion appeared attenuated 15 min after L-NAME (phase II,
RVC 15 min after L-NAME: 26  10%; phase II, MVC
15 min after L-NAME: 17  5%, n  5), but this difference
was not statistically significant (Fig. 3, D and E).
As a control for nonspecific effects of L-NAME, we injected
the same amount of D-NAME (10 nmol) in a second group of
animals (n  5, baseline MAP: 109  7 mmHg; baseline HR:
322  17 beats/min). Microinjection of D-NAME by itself did
not cause any significant change in baseline values (MAP
before D-NAME: 108  6 mmHg vs. MAP after D-NAME:
109  7 mmHg; HR before D-NAME: 340  16 beats/min vs.
HR after D-NAME: 352  16 beats/min). D-NAME also did
not affect the changes in MAP, HR, and regional vascular
conductance elicited by AMPA microinjection. Thus the hind-
quarter vasodilation observed in phase III with AMPA micro-
injection (phase III, HVC control: 17  6%) remained after
pretreatment with D-NAME (phase III, HVC 5 min after
D-NAME: 23 10%; phase III, HVC 15 min after D-NAME:
19  12%; and phase III, HVC 45 min after D-NAME: 30 
13%, n  5).
DISCUSSION
This is the first study showing the physiological role of the
interaction between the non-NMDA receptor (AMPA) activa-
tion and NO produced endogenously in the NTS of conscious
rats. The present data show that inhibition of NO production
within the NTS changes the hemodynamic responses elicited
by AMPA receptor stimulation.
Activation of the AMPA receptor in the NTS of conscious
rats induces an initial reduction in hindquarter blood flow that
is followed by a large increase (9). Increased blood flow is due
to hindquarter vasodilation. The origin and pathway of this
vasodilation was not clear, but studies of Davisson et al. (6, 7)
suggested a neurogenic hindquarter vasodilation mediated by
release of preformed stores of nitrosyl factors after sympathetic
Fig. 3. Hemodynamic responses to microin-
jection of AMPA (10 pmol/100 nl) before and
5, 15, and 45 min after microinjection of
L-NAME into the NTS of conscious rats (n 
6). A and B: changes in MAP (MAP,
mmHg) and HR (HR, bpm), respectively.
C–E: percent changes in vascular conduc-
tance of the hindquarter (HVC%, C), renal
(RVC%, D), and mesenteric vascular beds
(MVC%, E). Data are expressed as means
SE. *P  0.05, significant change from basal
(MAP phase II: all time points, phase III: 15
min; HR phases I and II: all time points;
HVC% phase II: 5, 15, and 45 min, phase
III: control; RVC% and MVC% phase II:
all time points). †P  0.05, significant re-
sponse different from control (HVC%
phases II and III: all time points).
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stimulation. Colombari et al. (4) showed a hindquarter vaso-
dilation elicited by activation of glutamatergic receptors in the
NTS that was abolished after systemic L-NAME administra-
tion. The systemic administration of L-NAME probably
blocked NOS in endothelial cells and nerve terminals in the
vasculature and anywhere else NOS was present.
In the present study, we observed that hindquarter blood
flow changes elicited by AMPA stimulation were modified
after L-NAME microinjection within the NTS. Our group (10)
recently reported that inhibition of NOS in the NTS of anes-
thetized rats attenuates baroreflex and cardiopulmonary reflex
inhibition of renal nerve discharge, which suggests that NO can
be functionally important in modulation of cardiovascular
reflexes through the CNS. The pool of preformed NO present
within the NTS neurons and that formed and/or released by
stimulation of glutamatergic receptors would, in some way,
activate a system to cause vasodilation and an increase in
hindquarter blood flow. The response observed at the hind-
quarter bed combines AMPA stimulation response (initial
vasoconstriction) and vasodilatatory system activation: 1)
quick and accentuated fall in blood flow that returns to basal
levels when blood pressure increases, and 2) vasodilation of
the hindquarter bed that becomes “visible” when vasoconstric-
tion is finished. In the same way, when the NO-mediated
pathway is inhibited (NOS inhibition), the hindquarter vaso-
constrictor effect of AMPA lasts longer and is enhanced in
magnitude, as noticed, because blood pressure level is in-
creased.
L-NAME is a potent in vitro and in vivo NOS inhibitor that
competes with L-arginine for the substrate-binding site at the
enzyme (39). Blockade of NOS activity by injection of L-
NAME in the NTS seems to be dose related (18), because in
high concentration, L-NAME is more selective to endothelial
NOS and local vasoconstriction can cause cell damage. The
dose used in our studies did not change baseline blood pres-
sure, heart rate, regional blood flow, or renal nerve activity
(10). NO present and synthesized in NTS neurons has inter-
and intracellular effects. We do not know whether the results
observed in the present study during NOS inhibition can be
attributed to postsynaptic modulation, because all of the drugs
were microinjected. Our group’s previous single-unit study (8)
showed that iontophoresis of L-NAME does not alter sponta-
neous discharge but significantly decreases the number of
action potentials evoked by iontophoretic application of
AMPA in NTS neurons receiving vagal afferents inputs, sug-
gesting that NO facilitates glutamate transmission through
AMPA receptors within the NTS neurons.
In addition to our previous studies by our group (8, 10) and
other findings in the literature, the present study suggests that
NO formed and released within the NTS may modulate the
response elicited by glutamatergic transmission, including the
effects observed on the hindquarter limb. NO was first char-
acterized in the CNS as an intercellular messenger responsible
for the increase in cGMP levels after activation of glutamater-
gic receptors (14). It is known that central NO is produced by
NOS, which is activated by Ca2	 through calmodulin. NO
activates soluble guanylyl cyclase (sGC), stimulating the pro-
duction of cGMP. The anatomic relationship among sGC
immunoreactivity, nNOS, glutamate, and glutamate receptors
suggests that NO and glutamate interactions in the NTS in-
volve sGC (31). The evidence that central NO is involved in
peripheral functions has been growing. NO can influence brain
development, memory, synaptic plasticity, and modulation of
neuroendocrine responses (12). Anatomic and other studies in
the last decade support the idea that NO modulates NTS
function once nNOS is found in cell bodies, terminals, and
fibers of the NTS (2, 21, 26, 28, 30).
We propose a NO-mediated vasodilatatory system (nitroxi-
dergic pathway) within the NTS responsible for the modulation
of the sympathetic outflow (vasoconstrictor response) when
glutamatergic afferents are activated. The integrated response
observed with AMPA microinjection into the NTS would be a
result of the activation of both systems: vasoconstrictor and
vasodilatatory. If one system is blocked, what we see is only
Fig. 4. Schematic representation showing
our hypothesis of the mechanism activated by
NO formed and/or released within the NTS in
modulation of glutamatergic transmission
during stimulation of the cardiovascular in-
puts. SP, substance P; L-glu, L-glutamate.
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the cardiovascular effect of one system (vasoconstrictor) with-
out the modulatory influence of the other (vasodilatatory).
The exact pathway of central formed NO in modulating
glutamatergic receptor-mediated responses in NTS is not fully
understood. Increases in extracellular NO levels have been
shown to induce glutamate release (24), and microinjections of
AMPA and NMDA have been shown to increase NO release
(24, 33). It was recently shown that the distribution of NTS
neurons that project to the pressor area of rostral ventrolateral
medulla (RVLM) is similar to that containing nNOS neurons,
suggesting that NO within the NTS may influence cardiovas-
cular function through the NTS-RVLM pathway (20).
We think there are two distinct mechanisms leading to
production/release of NO. The first one (see “1” in Fig. 4)
involves intracellular production and release of NO by AMPA
receptor stimulation within NTS neurons. The pool of NO that
is formed facilitates glutamatergic transmission and activates
the pathway (see “2” in Fig. 4) that will cause vasodilatatory
response by release of NO at the sympathetic nerve terminals
in the hindquarter vascular bed. The exact interaction of NTS
and other medullary sites resulting in the activation and/or
deactivation of this pathway is still unclear.
Figure 4 shows how NO may be involved in the changes we
found in hindquarter blood flow. Activation of cardiovascular
afferents such as baroreceptors, chemoreceptors, and cardio-
pulmonary receptors increases the release of glutamate in the
NTS. Glutamate acts on AMPA receptors at the postsynaptic
membrane and triggers the production of NO (1). Because NO
is a diffusible compound, it may act in the same and/or
adjacent cells and stimulate the release of glutamate through
presynaptic receptors, and it also may change the release of
other neurotransmitters such as GABA, substance P, and ACh.
The NO mobilized by AMPA receptor activation within the
NTS would be responsible for hindquarter vasodilation (acti-
vation of the vasodilatatory nitroxidergic pathway) to restore
blood pressure levels.
Overall, the present data show that centrally formed NO can
affect glutamatergic transmission within the NTS to modulate
cardiovascular responses. The specific function or mechanism
of this interaction remains to be elucidated, but it could also
involve the action of NO in controlling release of other neu-
rotransmitters.
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